PE
DYN icon

Point72 Europe’s Dyne Therapeutics DYN Stock Holding History

Point72 Europe’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$31.5K Buy
+2,487
New +$28.4K ﹤0.01% 420

Other funds holding DYN

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Point72 Europe's DYN Position: Q3 2025 in Review

Point72 Europe opened a new position in Dyne Therapeutics (DYN) in Q3 2025: 2,487 shares worth $31.5K. The stake represents ﹤0.01% of the portfolio and ranks #420 among its holdings.

207 funds tracked by Wall St. Rank hold DYN as of Q3 2025.

  • Point72 Europe held 2,487 shares of Dyne Therapeutics worth $31.5K as of Q3 2025.
  • Dyne Therapeutics was a new Point72 Europe position in Q3 2025.
  • Dyne Therapeutics made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #420 holding.
  • 207 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.